52nd Annual Meeting
December 8-12, 2013
The Westin Diplomat Resort & Spa
Hollywood, Florida

President: David A. Lewis, M.D. Program Committee Chair: Randy D. Blakely, Ph.D. Program Committee Co-Chair: Pat R. Levitt, Ph.D.
This meeting is jointly sponsored by the Vanderbilt University School of Medicine Department of Psychiatry and the American College of SCHEDULE
Friday, December 6, 2013
11:00 am – 5:00 pm SOBP Council Meeting
Saturday, December 7, 2013
Council Meeting
Membership Committee Meeting
2:00 pm – 4:00 pm NPP & NPPR Editors Meeting

4:00 pm – 5:30 pm
Publications Committee Meeting

4:00 pm – 5:30 pm
Ethics Committee Meeting

5:30 pm – 6:30 pm
ACNP Website Editors Meeting

6:30 pm – 8:30 pm
Travel Award Reception (by invitation)
Sunday, December 8, 2013
Neuropsychopharmacology Reviews Plenary: "Frontiers in
Discovery and Neurotherapeutics"

11:30 am – 1:00 pm Past President's Luncheon
11:30 am – 1:00 pm
11:30 am – 1:00 pm
Program Committee Meeting

11:30 am – 1:00 pm
Liaison Committee Meeting
11:30 am – 1:00 pm NPP Editorial Board Meeting (by invitation)

1:00 pm – 2:30 pm
Q&A Forum with NIH Institutes Directors

2:30 pm – 6:30 pm
Paper Sessions: "Hot Topics"
7:00 pm – 9:00 pm Opening Reception
Monday, December 9, 2013
6:45 am – 8:00 am CDI Booster Session

8:00 am - 11:30 am
President's Plenary: "Neural Circuitry Structure and Plasticity:
Substrate for Brain Disorders and Novel Therapeutics"
Gina Turrigiano, Ph.D., Homeostatic Plasticity: Keeping your Brain
in Balance

Z. Josh Huang, Ph.D., Genetic Dissection of GABAergic Circuits in
Chandeliers Light up the Path

Carla Shatz, Ph.D., Surprise at the Synapse: MHC Class I, Pruning
and Plasticity

Amy Arnsten, Ph.D., Dynamic Modulation of Dorsolateral
Prefrontal Cortex Microcircuits: Focus of Vulnerability in Mental 10:30 am - 4:30 pm Poster Viewing
11:30 am - 1:30 pm Women's Luncheon (reservations requested)
Guest Speaker: TBD
1:30 pm – 3:00 pm Distinguished Lecture – Huda Y. Zoghbi, M.D.
The Story of Rett Syndrome and the insight it provides into Neuropsychiatric Disorders Mini-Panel Sessions
Session 1
Neuronal Immaturity in Schizophrenia
Chair: Mickey Matsumoto
GABA Signaling in Postmortem Human Brain and Schizophrenia: A Question of
Speaker: Joel Kleinman
Immature Neurons in Schizophrenia? Support from Investigations on Proteoglycan
Speaker: Sabina Berretta
Immature Dentate Gyrus as a Candidate Endophenotype of Neuropsychiatric Disorders
Speaker: Tsuyoshi Miyakawa
Session 2
Social Processes Initiative in Neurobiology of the Schizophrenia(s)
Chair: Anil Malhotra
The Neural Circuitry of Social Impairments in Schizophrenia Spectrum Disorders
o Robert Buchanan  Altered Structural and Functional Network Topology in Deficit Schizophrenia
o Philip Szeszko  Network Topology in Deficit Schizophrenia, Nondeficit Schizophrenia, and Bipolar
Sisorder: From Circuits to Functional Outcome
o Aristotle Voineskos Panel Sessions

Session 1
Kicking Over the Traces - Noncatecholic Biogenic Amines and Their Receptors
Chair: David Grandy
Evidence from Molecular Modeling, Site-Directed Mutagenesis and BehavioralTesting
Indicate Trace Amine-Associated Receptor 1 is a Methamphetamine Receptor
Selective TAAR1 Ligands and Transgenic Animal Models Reveal a Role of TAAR1 in
Cognitive, Neurologic and Psychiatric Disorders
o Raul Gainetdinov  Trace Amine Associated Receptor 1 Modulation of the Rewarding and Immunological
Effects of Drugs of Abuse Supports its Relevance as a Therapeutic Target
o Gregory Miller  The Activation of Intracellular Signaling Systems by Amphetamines: A Potential Role for
Trace Amine Receptors
 Discussant: David Shurtleff Session 2
Autism Spectrum Disorders: From Rare Chromosomal Abnormalities to Common Molecular
Chair: Ted Abel
Role of copy number variants in autism spectrum disorders
o Santhosh Girirajan  Comprehensive phenotyping of mouse autism models
Tbx1 and Sept5 contribute to behavioral and neuronal phenotypes in mouse models of
22q11.2-associated ASD
The Translation of Translational Control in Autism Spectrum Disorders
 Discussantear: Alice Luo Clayton Session 3
Circuitry Underlying Obsessive-compulsive Disorder: Lessons from Deep Brain Stimulation and
Ablative Surgery
Chair: Suzanne Haber
Ablative Limbic System Surgery for the Treatment of OCD
The circuitry of deep brain stimulation and cingulatomy: monkey tracing vs. human
DBS of ventral striatum in rodents modulates fear extinction via prefrontal and
orbitofrontal projections
Deep Brain Stimulation for Intractable OCD: Population and Outcomes
o Benjamin Greenberg  Discussant: Scott Rauch
Session 4
The Role of Inflammation in the Pathophysiology of Mood, Aggressive and Medical Disorders: a
Deadly Combination
Chair: Emil Coccaro
Plasma Markers of Inflammation are Elevated in Subjects with Intermittent Explosive
Disorder and Correlate Directly with Aggression in Human Subjects
Stress, Trauma, and Inflammation in Non-Psychiatric Subjects
o Janice Kiecolt-Glaser  Inflammation and Depression: Sleep Disturbance Moderates Induction of Depressed
Mood by an Inflammatory Challenge
Transcriptional Signatures Related to Glucose and Lipid Metabolism Predict Treatment
Response to the Tumor Necrosis Factor Antagonist Infliximab in Patients with
Treatment-Resistant Depression

o Jennifer Felger  Discussant: Charles B. Nemeroff
Session 5
Can Biology Inform Treatment Prediction and Selection in Depression?
Chair: Amit Etkin
Large-scale Pre-treatment Prediction of Remission with Antidepressants for Individual
Patients Based on Cognitive and Emotional Test Performance, as well as Its
Neuroimaging Correlates

Initial Results of the NIMH-funded EMBARC Study
o Madhukar Trivedi  Inflammatory Biomarkers Predict Differential Outcome of Depression Treatment with
Escitalorpam and Nortriptyline in the GENDEP Project
Brain Serotonin 1A Receptor Binding as a Predictor of Treatment Outcome in Major
Depressive Disorder
 Discussant: Thomas R. Insel
Session 6
Structural and Functional Brain Changes in Young People at Risk for Severe Mental Illness
Chair: Martin Alda
Clinical Stages and Developmental Trajectories of Bipolar Disorder: Family-based
Population Neuroscience and Psychiatric Genetics: A Two-way Street
Vulnerability or Resilience? Brain Developmental Studies in Non Psychotic Siblings of
Childhood Onset Schizophrenia Patients
Neuroanatomical Changes in Bipolar Disorders - Causes Versus Consequences of the
 Discussant: Mary L. Phillips Poster Session I with Reception

7:30 pm - 9:00 pm
Issue Oriented Study Groups
Session 1
The Challenges of Designing and Interpreting Clinical Trials with Depot Antipsychotics
Chair: W. Wolfgang Fleischhacker
Raymond Sanchez
Srihari Gopal
Maxine Patel
Stephan Heres
Keith Nuechterlein
Hiroyuki Uchida
Session 2
Mental Illness, Violence and the Gun Control Debate: Evidence, Policy, Privacy and Stigma - on
Behalf of the ACNP Ethics Committee

Chair: David Pickar
Co-Chair: Jerrold Rosenbaum
David Pickar
Jerrold Rosenbaum
Emil Coccaro
Kenneth Davis
Paul Appelbaum
Brian Frosh
J. Dee Higley
Session 3
New Models of Open Innovation to Rejuvenate the Biopharmaceutical Ecosystem, A Proposal by
the ACNP Liaison Committee
Chair: Dean Wong
Co-Chair: Lisa Gold
Dean Wong
Robert Innis
Lawrence Sung
Steven Paul
Phillip Phan
Steven Grant
Husseini Manji

Session 4
The Assessment Of Suicidal Ideation, Behavior & Risk: At Baseline; As a Measure of Clinical
Outcome, and/or as a Treatment Emergent SAE
Chair: Roger Meyer
Co-Chair: Eric Youngstrom
Ahmad Hameed
John Greist
Phillip Chappell
J. John Mann
David Sheehan
Cheryl McCullumsmith
Larry Alphs
Richard Shelton
Paula Clayton
Kelly Posner

Session 5

Medical and Non-Medical Use of Stimulant Drugs for Cognitive Enhancement
Chair: James Swanson
William Pelham
Trevor Robbins
Barbara Sahakian
James McCracken
Susanna Visser
Ruben Baler
Kathleen Merikangas
Raul Gonzalez
James Waxmonsky
Tim Wigal
Marc Lerner
Wilson Compton
Tuesday, December 10, 2012
6:45 am – 8:00 am CDI Booster Session
7:00 am – 6:00 pm
7:30 am – 8:30 am
ACNP Leadership & Institute Directors

7:00 am – 8:30 am
Education & Training Committee Meeting

7:00 am – 8:30 am
Membership Advisory Task Force Meeting

8:30 am – 11:00 am
Mini-Panel Sessions

Session 1

Biochemical and Behavioral Pharmacology of Synthetic Cathinone Derivatives Found in
Psychoactive Bath Salts Products
Chair: Richard Rothman
Effects of newly-emerging synthetic cathinone derivatives on monoamine transporter
function in rats
o Michael Baumann  Intravenous self-administration of 3,4-methylenedioxypyrovalerone (MDPV) and 4-
methylmethcathinone (4-MMC, mephedrone) in rats
Abuse-related and abuse-limiting effects of synthetic cathinone “bath salt―
derivatives on intracranial self-stimulation in rats

Session 2
After the Trauma: Developmental Trajectories from Childhood to Adult Psychiatric Disorders
Chair: Michael De Bellis
The Neurobiology of PTSD Symptoms in Maltreated Children and Adolescents
o Michael De Bellis  Sex-specific Effects of Childhood Emotional Abuse on Affective Processing in Bipolar
Disorder Patients
o Katherine Burdick  The Long-Term Consequences of Childhood Maltreatment: Effects on Brain Structure
and Subclinical Psychopathology in Healthy Adults
o Pamela DeRosse 8:30 am – 11:00 am Panel Sessions

Session 1
Augmentation of Antidepressant Response by Autoreceptor-Mediated Mechanisms: Clinical
Experience and Mechanisms of Action
Chair: Salomon Langer
Autoreceptor-mediated Regulation of Neurotransmission: Pharmacological Targets and
Potential for Improved Treatment of Major Psychiatric Disorders
o Salomon Langer  Rapid Augmentation of Antidepressant Effect in Treatment-resistant MDD by Add-on
Low Dose Aripiprazole
Low Doses of Atypical Antipsychotic Drugs Added to Selective Serotonin Inhibitors
Produce a Ketamine-like Facilitation of Prefrontal Glutamatergic Neurotransmission
o Torgny Svensson  Emerging Role of Atypical Antipsychotics as Add-on Therapy in Major Depression
o Speaker Siegfried Kasper  Discussant: Dennis S. Charney
Session 2
Neuroactive Steroids and Oxysterols as Endogenous Modulators of GABA and Glutamate
Receptors: Basic Mechanisms and Therapeutic Implications
Chair: Steven Paul
GABAergic Neurosteroids as Novel Targets for Therapeutic Drug Development in
o Charles Zorumski  Natural and Synthetic Neuroactive Steroids and Oxysterols as Potent NMDA Receptor
Allosteric Modulators: Therapeutic Considerations
Neuroactive Steroids Ganaxolone and Allopregnanolone in the Treatment of Epilepsy,
Traumatic Brain Injury, and Neurobehavioral Disorders
o Michael Rogawski  Neurosteroids as Novel Therapeutics and Biomarker Candidates in Schizophrenia and
o Christine Marx  Discussant: Bruce S. McEwen
Session 3
The Future of Translational Research in Addiction
Chair: Harriet de Wit
Cross-species Behavioral Tests for Investigations of Addictive and Psychiatric Disorders
Neurocircuitries for Social Stress and Drug Abuse: Novel Targets for Intervention
Towards consilience in animal and human behavioural models in addiction
o David Stephens  Identifying the molecular determinants of inhibitory control problems in addictions
o J. David Jentsch  Discussant: Harriet de Wit Session 4
At the Crossroads of Physics, Physiology, and Psychiatry: Rational Design of Noninvasive
Neuromodulation Therapies
Chair: Sarah Lisanby
Targeting of Transcranial Direct Current Stimulation: Insights from Cellular and
Computational Models
Optimizing Stimulus Pulse Characteristics for Transcranial Magnetic Stimulation and
Electroconvulsive Therapy Via Device Development, Computational Modeling, and
Biophysically-motivated Dosing Paradigms

o Angel Peterchev  Mechanisms of Targeting Cortical State Dynamics with Neuromodulation
o Flavio Frohlich  Enhancement of Working Memory in Sleep Deprived Young Adults and in Elderly Adults
using rTMS Informed by Covariance-modeled fMRI
 Discussant: Zafiris J. Daskalakis
Session 5
Nutrition, Neurodevelopment, and Risk for Schizophrenia and Autism: From Epidemiology to
Chair: Joshua Roffman
Periconceptional folic acid and neurodevelopmental disorders: historical context and
current research
Effects of Periconceptional Folate on Language Delay and Autism Spectrum Disorders:
The Norwegian Mother and Child Cohort Study
o Camilla Stoltenberg  Longitudinal Effects of In Utero Folate Exposure on Cortical Thickness: Implications for
Neurodevelopmental Disorders
o Joshua Roffman  The placental and neuronal methylomes at the interface of genetic and environmental
risk and protective factors in autism
o Janine LaSalle  Discussant: Donald Goff
Session 6
Peripheral Immune and Endocrine Pathways as Markers of PTSD Risk and Symptom
Development: Evidence from Prospective Studies
Chair: Victoria Risbrough
Longitudinal Plasma Testosterone Trajectory and its Relation to Combat, Temperament
and PTSD
o Eric Vermetten  Evidence for Plasma C-Reactive Protein Concentration as Biomarker of PTSD Risk
Blood-Based Gene-Expression Predictors of PTSD Risk and Resilience among Deployed
Marines: A Pilot Study
Exaggerated Threat Sensitivity and Avoidance as Contributors to Elevated Inflammation
in Posttraumatic Stress Disorder: Data from the Mind Your Heart Study
o Aoife O'Donovan  Discussant: Thomas Neylan Poster Viewing

11:00 am – 12:30 pm

11:00 am – 12:30 pm
Public Information Committee Meeting

11:00 am – 12:30 pm
ACNP Corporate Liaison Luncheon (by invitation)
11:30 am – 12:30 pm SOBP Biological Psychiatry Journal Editors Meeting

11:30 am – 1:30 pm
Data Blitz

1:30 pm – 3:00 pm
Career Development Session
Mini-Panel Sessions
Session 1
Emerging Role of the Primary Cilium in Neuropsychiatric Disorders
Chair: Bernard Lerer
The Role of AHI1 in Regulating Primary Cilia Signaling
o Russell Ferland  Functional Significance of Primary Cilia to GPCR Signaling and Relationship to
Neuropsychiatric Disease
o Mark Von Zastrow  Abnormal Response to Stress in Heterozygous AHI1 Knockout Mice: A Consequence of
Primary Ciliary Dysfunction?
Session 2
Adolescent Brain Development and Affective Disorders: The Role of Reward and Threat
Chair: Erika Forbes
Adolescent VTA Neurons Exhibit Latent Neuronal Correlate of Reward Opportunity
o Bita Moghaddam  Adolescents' Neural Response to Personally Relevant Social Reward Is Associated with
Severity of Mania and Depression
Parallel Processing Brain Networks Illustrating Dynamic Interplay Between Emotional
and Cognitive Operations in Developing Youth with Affective Disorder
o Ellen Leibenluft 3:00 pm - 5:30 pm Panel Sessions

Session 1
Treating Addiction: Should We Aim High or Low?
Chair: Marina Wolf
Rapid LTP in accumbens is a common feature of relapse to multiple classes of addictive
Synaptic Depression via Positive Allosteric Modulation of mGluR1 Suppresses Cue-
induced Cocaine Craving
Silent Synapse-based Circuitry Reorganization in Cocaine Craving
Withdrawal from Acute Amphetamine Potently Down-Regulates VTA Dopamine Neuron
Activity: Reversal by Ketamine
 Discussant: Anissa Abi-Dargham
Session 2
Anxiety and the Striatum, an Unusual Suspect
Chair: Monique Ernst
Neural Response in Striatum Varies by Reward Magnitude, Decision Making, and
Anxiety Diagnosis in Adolescents
Cortico-amygdala Pathways form Hierarchical Networks that Predict Output to the
The Impact of Induced Anxiety on Ventral Striatal Response to Aversive and Appetitive
Prediction Error Signals
o Oliver Robinson  Endocannabinoids in the Dopaminergic Control of Punishment and its Avoidance
 Discussant: Mauricio Delgado
Session 3
Posttraumatic Stress Disorder: From Markers to Mechanisms
Chair: Murray Stein
Identification of Novel Gene Regulatory Networks Associated with PTSD: Evidence from
Whole Genome Studies Examining DNA Methylation
o Douglas Williamson  Allele Specific Epigenetic Modifications - A Molecular Mediator of Gene - Environment
Interactions in Stress Related Psychiatric Disorders?
o Torsten Klengel  Opioid Receptor-Like 1 (OPRL1) is Involved in Amygdala-dependent Fear in Mice and
Humans with PTSD
Contextual Processing Deficits in PTSD: Translational Studies
o Israel Liberzon  Discussant: Charles R. Marmar
Session 4
Biotypes of Psychosis
Chair: Carol Tamminga
Phenotypic characterization of the schizophrenia- bipolar disorder continuum.
o Matcheri Keshavan  Identification of distinct psychosis biotypes with multivariate taxometric analyses of
neuro-pathologically relevant biomarkers
o Brett Clementz  Validating Psychosis Biotypes
o Carol Tamminga  Multivariate fusion methods identify gene components associated with heritable resting
state fMRI abnomalities in BSNIP probands and relatives
o Godfrey Pearlson  Discussant: Steven Edward Hyman
Session 5
An Update from the Clinic on mGluR2/3 Approaches for Treating Schizophrenia –
Understanding Human Circuit Engagement through to Recent Clinical Trials
Chair: Nicholas Brandon
The Development of Pomaglumetad Methionil as an Innovative Glutamate-based
Pharmacotherapy for Schizophrenia
Discovery and early clinical development of novel mGlu2 receptor PAMs
o Hilde Lavreysen  AZD8529 - an mGluR2 positive allosteric modulator for the treatment of schizophrenia
Efficacy of an mGluR2 agonist (LY354740) and an mGluR2 positive allosteric modulator
(AZD8529) in attenuating ketamine effects in humans
 Discussant: Daniel R. Weinberger
Session 6
Pathophysiology and Treatment of Obesity and Glucose Dysregulation in Schizophrenia
Chair: L. Jarskog
Effect of metformin on weight in patients with schizophrenia with impaired fasting
Dopamine, Clean Up Your "AKT!" Restoring Insulin Signaling in Brain
o Aurielio Galli No effect of adjunctive, repeated dose intranasal insulin treatment on body metabolism in
patients with schizophrenia
Dysglycemic Signals in Antipsychotic-Treated Children and Adolescents with
Schizophrenia-Spectrum Disorders: Trajectories, and Moderating and Mediating Factors
o Christoph Correll  Discussant: Robert W. Buchanan 5:30 pm – 7:30 pm Poster Session II with Reception
6:00 pm – 11:00 pm Council Meeting with Committee Chair Reports
Wednesday, December 11, 2013
ASCP Board of Directors Meeting
CDI Booster Session
Mini-Panel Sessions

Session 1
Are the Putative Therapeutic Effects of Kappa-opioid Antagonists Explained by Anti-stress
Chair: William Carlezon
Disruption of Kappa-opioid Receptor Actions Reduces Stress Effects on Cognitive
Function and Anxiety-like Behavior
o Ashlee Van't Veer  Dynorphin-kappa Systems in Compulsive-like Responding with Extended Access to Elicit
The Dissociable Effects of Kappa-Opioid Receptor Activation on Intolerance to Delay and
Response Inhibition
o Brendan Walker

Session 2
Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS, CNTRaCs and
Chair: Cameron Carter
New Neuroscience Based Cognitive Paradigms for Biomarker Research in Schizophrenia
Developing Imaging Biomarkers for Treatment Development: Beyond CNTRICS,
o Angus MacDonald  Imaging biomarkers for psychiatric disorders: the NEWMEDS experience
o Andreas Meyer-Lindenberg 8:30 am - 11:00 am Panel Sessions

Session 1
Manipulating BDNF-TrkB Signaling in Brain Disorders: Complex Regulation and Cellular &
Systems Level Interactions as Novel Substrates for Translational Medicine
Chair: Keri Martinovich
Differential Contribution of Individual BDNF Splice Variants to Brain and Behavioral
o Keri Martinowich  Role of Slitrk5 in Regulating BDNF Dependent Signaling
Convergence of BDNF and Glucocorticoid Receptor Signaling
Synaptic Repair: Translating BDNF Biology into New Medicines for Psychiatric Diseases
 Discussant: Ronald S. Duman

Session 2
The Ventromedial Prefrontal Cortex in Conditioning and Extinction in Chronically Relapsing
Chair: Rita Goldstein
Factors that impact the functional reactivity of the fear extinction network across
o Mohammed Milad  Retention of Extinction Learning for Monetary Reward in Cocaine Addiction: Role of the
Amygdala and VMPFC
o Rita Goldstein  Deficits in Ventromedial Prefrontal Cortex Group1 Metabotropic Glutamate Receptors
Underpin Cognitive Dysfunction During Protracted Cocaine Withdrawal
o Karen Szumlinski  Role of ventral medial prefrontal cortex (mPFC) and its projections to accumbens shell on
context-induced reinstatement of heroin seeking in rats
o Jennifer Bossert  Discussant: Gregory J. Quirk

Session 3
α4β2-Nicotinic Acetylcholine Receptors in Schizophrenia: Implications for Smoking Cessation
and Therapeutics
Chair: A. Eden Evins
In vivo evidence for β2*-nAChR upregulation in smokers as compared to nonsmokers
with schizophrenia
o Irina Esterlis  Nicotinic CHRNA4 Exon 5 Genotype Predicts Clinical Outcome in Schizophrenia and
Neuroleptic Drug Treatment-Response
o Georg Winterer  Examining the α4β2Nicotinic Partial Agnoist Varenicline on the Tobacco Abstinence
Syndrome in Schizophrenia Versus Control Smokers
Extended Duration Pharmacotherapy with Varenicline Prevents Relapse to Smoking in
Adult Smokers with Schizophrenia
 Discussant: Tony P. George
Session 4
New Directions for Optogenetics: Investigating Plasticity Mechanisms Underlying Psychiatric
Chair: Helen Simpson
Brief Repeated Cortico-striatal Stimulation Leads to Persistent OCD-Relevant Behaviors
o Susanne Ahmari  Cortical Control of Brainstem Neuromodulatory Systems in Motivated Behavior
o Melissa Warden  Different Patterns of Stimulation in Projections from VTA to PFC Exert Distinct Effects
on Behavioral Flexibility
Molecular and Circuit Basis of Impaired Hippocampal-Prefrontal Synchrony in a Mouse
Model of Schizophrenia Predisposition
 Discussant: Karl Deisseroth Session 5
Alterations of the Glutamate Cycle in Severe Mental Illness
Chair: Adrienne Lahti
Glutamatergic abnormalities in medicated and unmedicated patients with schizophrenia
o Adrienne Lahti  Abnormalities of glutamate transporter expression in schizophrenia: Evidence for
increased glutamate reuptake and altered subcellular partitioning of EAAT2 interacting

o Robert McCullumsmith  Psychosis and cognition related to different brain glutamate pools in schizophrenia
Functional Implications of Altered In Vivo Glutamate and GABA Systems in
 Discussant: Kelvin O. Lim
Session 6
Epigenetic Mechanisms in Neuropsychiatric Disorders
Chair: Paul Kenny
MicroRNAs and Drug Addiction
Global Transcriptome Analysis of Human Cerebrospinal Fluid
o Claes Wahlestedt  Insights into the Roles of the Methyl-DNA Binding Protein MeCP2 in Addictive-like
MicroRNA 135 is Essential for Chronic Stress Resiliency, Antidepressant Efficacy and
Intact Serotonergic Activity
 Discussant: Eric Nestler
10:30 am - 4:30 pm
Poster Viewing
11:15 am - 12:30 pm Business Meeting
(ACNP Associate Members, Members and Fellows only) 12:00 pm – 2:00 pm SOBP Program Committee Meeting

12:30 pm - 2:00 pm
Buffet Lunch
12:30 pm – 2:00 pm Travel Award Luncheon (Awardees & Mentors Only)
3:00 pm – 5:30 pm Mini-Panel Sessions
Session 1
Human Brain Evolution and Comparative Epigenomics
Chair: Schahram Akbarian
Decoding the Molecular Evolution of Cognition
o Genevieve Konopka  Divergent Whole Genome Methylation Maps of Human and Chimpanzee Brains Reveal
Epigenetic Basis of Human Regulatory Evolution and Disease Susceptibility
Neuronal Epigenome Mapping in Human and Non-human Primate Prefrontal Cortex
o Jogender Singh Tushir  Discussant: Linda Porrino
Session 2
Intergenerational Transmission of Trauma – From Animal Models to Humans
Chair: Kerry Ressler
Epigenetic Markers in the GR and FKBP5 Genes in Children of Holocaust Survivors
Transgenerational Imprints on Structure and Function in the Mammalian Nervous
Behavioral and Neural Mechanisms of the Intergenerational Transmission of Trauma
o Jacek Debiec 3:00 pm - 5:30 pm Panel Sessions

Session 1
Legal Damages: New Insights into Chronic Marijuana Effects on Human Brain Structure and
Chair: Steven Grant
Impact of Chronic Marijuana Use on Reward and Control Brain Networks
o Francesca Filbey  Effect of Long-term Cannabis use on Axonal Fiber Connectivity
o Andrew Zalesky  Unmotivated? Signatures of blunted dopaminergic responsiveness in chronic marihuana
Multimodal MR Imaging in Adolescent MJ Users
o Deborah Yurgelun-Todd
Session 2
Glutamate-dopamine interactions in nicotine and cocaine dependence: Biomarkers and Therapy
Chair: Dean Wong
In Vivo Imaging of Human mGluR5 and nAch receptors with PET: Dynamic Duo for
Abuse Studies and Drug Occupancy?
Dopamine Activity and Reward Processing in Smokers Before and After Smoking
Cessation: Combined [18F]FDOPA/fMRI Studies
o Gerhard Grander  Reduced mGluR5 Receptor Binding in Smokers and Ex-smokers Determined by
[11C]ABP688 Positron Emission Tomography: Clinical and Scientific Relevance
Understanding Glutamate, Acetylcholine and Dopamine Interactions in Nicotine
Dependence using Animal Models
o Manoranjan D'Souza  Discussant: Athina Markou
Session 3
Public-Private Repositioning Partnerships: A New Path to Achieve Target Validation and Proof
of Concept for Novel CNS Indications
Chair: Linda Brady
Drug Repositioning Through Open Innovation - An Industry Perspective
The MRC/AstraZeneca Mechanisms of Disease Compound Sharing Initiative
o Christopher Watkins  NCATS/NIH-Industry Pilot Program on Drug Repositioning
o Christine Colvis  Open Innovation and Mobile Health Technology to Improve and Accelerate Clinical
o Tomasz Sablinski Session 4
Multidimensional Data Integration and Causality: A Systems Approach for Unraveling the
Molecular Architecture of Mental Disorders
Chair: Thomas Lehner
Elucidating the Complexity of Psychiatric Disorders via the Integration of High-
Dimensional, Multiscale Data
Cis and trans data integration to find mechanisms causing psychiatric disorders
o Edwin Van Den Oord  The ENIGMA Consortium: Meta-Analyzing Neuroimaging and Genetic Data from 125
Computational analysis of complex human disorders
o Andrey Rzhetsky  Discussant: Steven Edward Hyman
Session 5
Early Stress and Emotion Dysregulation
Chair: Christian Schmahl
Weakening Fear Memories as a Potential Treatment for Posttraumatic Stress Disorder
Effect of Direct Eye Contact in PTSD Related to Interpersonal Trauma: An fMRI Study
of Activation of an Innate Alarm System
Examining the genetic underpinnings of the amygdala habituation deficit in borderline
personality disorder
o M. Mercedes Peres-Rodriguez  Influence of Dissociation on Emotional Distraction in Borderline Personality Disorder
o Annegret Krause-Utz  Discussant: Andreas Meyer-Lindenberg
Session 6
Neurobiological Regulation of Palatable Food Binging and Seeking
Chair: Jacqueline McGinty
Extended amygdala-hypothalamic inhibitory circuits regulate feeding
Cholinergic Control of Food Intake: Mechanisms Highjacked by Nicotine
o Marina Picciotto  Serotonin Control in the Proclivity for High Impulsive Action and Binge Eating
o Kathryn Cunningham  Neural Correlates of Craving, Cognitive Control and Reward Processing in Obesity and
Binge-Eating Disorder
 Discussant: Jacqueline F. McGinty Poster Session III with Reception
Thursday, December 12, 2013
7:00 am – 8:00 am ACNP/AsCNP/CINP/ECNP Meeting
Panel Sessions

Session 1
Molecular Regulation and Clinical Applications of Phosphodiesterase 4, the Major Enzyme for
Degrading cAMP
Chair: Robert Innis
PDE4 in Huntington's Disease: Pathology of Cross-seeding of Huntingtin and
Amyloidogenic DISC1
Control of Mood by Selective Potentiation of cAMP Signaling in Ventral Striatum
o James Bibb Structural and Pharmacological Studies of PDE4 Subtype Selective Allosteric Inhibitors
Binding of 11C-(R)-rolipram to Phosphodiesterase 4 is Downregulated in Major
Depressive Disorder and Normalized with Antidepressant Treatment
Session 2
Naltrexone Revisited: New Findings Beyond Mu, Beyond Dopamine and Beyond Addiction
Chair: Robert Swift
Naltrexone Effects on GABAergic Neuroactive Steroids: Associations to Subjective
Responses and Pharmacogenetics
Neurocognitive Effects of Naltrexone
o Charlotte Boettiger  Naltrexone Pharmacotherapy for Adverse Metabolic Outcomes of Second Generation
Antipsychotic Agents
Microglial Activation Alters Reward Circuitry in Chronic Pain States
o Catherine Cahill
Session 3
Understanding Neurodevelopmental Risk Factors leading to Anxiety and Depression to Inform
Novel Early Interventions in Vulnerable Children
Chair: Ned Kalin
Neurobiology of Trauma and Infant Attachment: Short-term Benefits and Long-term
o Regina Sullivan  Primate Anxious Temperament and Amygdala Metabolism are Environmentally Sensitive
and Associated with Amygdalar Gene Expression
Glucocorticoid Receptor Activation Induced Epigenetic Changes and Their Moderation
by Genetic Variants as Potential Mediators of Risk and Resilience to Early Trauma-
associated Psychiatric Disorders

o Elisabeth Binder  The Pervasive and Persistent Neurobiological Consequences of Child Abuse and Neglect;
Clinical Implications
o Charles Nemeroff

Session 4
Brain on Fire: Inflammation in Neurological and Psychiatric Illness
Chair: Scott Russo
Pruning Developing CNS Synapses: An Active Role for Glia and Immune Molecules
Monitoring neuroinflammation and demyelination using Magnetic Resonance Imaging in
a preclinical setting
o Danielle Graham  Role of the peripheral immune system in stress-induced depressive behavior
Testing the Cytokine Hypothesis of Depression: Trials and Tribulations
Session 5
Melatonin and its Receptors: Important Players in Major Depressive Disorder
Chair: Pierre Blier
Melatonin-Mediated Potentiation of Physical Activity-Induced Neurogenesis in the
Dentate Gyrus of the C3H/HeN Mouse.
o Margarita Dubocovich  Interactions between Melatonin and 5-HT Receptors to Enhance Monoaminergic
Transmission in the Rat Brain
Impact of Hippocampal Neurogenesis on Cognition and Mood
A Pilot, Placebo-Controlled Study of Buspirone Plus Melatonin in Major Depressive

Session 6
Building a More Predictive Mouse: Humanized Mouse Models for Neuropsychiatric Disorders
Chair: Mark Geyer
The Tryptophan Hydroxylase Arg439His Knockin (Tph2KI) Mouse: A Naturalistic Model
of 5-HT Deficiency
o Jacob Jacobsen  Modeling the Contributions of Dopamine to ADHD via a Novel, Knock-In Mouse Model
Development and Characterization of Mice Humanzied for the COMTval158met
o Victoria Risbrough  DISC1-Boymaw Fusion Gene May Contribute to Major Psychiatric Disorders in the
Scottish Schizophrenia Family

Session 7
Broadening the Trajectories of Risk: Specific and Non-Specific Markers of Risk of
Chair: Kathleen Merikangas
Comorbidity of Medical and Psychiatric Disorders in the Neurodevelopmental Genomics
Cohort Study
o Kathleen Merikangas  The Study of Developmental Trajectories in Autism Spectrum Disorders; Lessons Learned
o Peter Szatmari  Clinical, Neurobiological and Circadian Correlates of the Onset and Course of Major
Mood Disorders: From Childhood Risk to Adolescent-onset and Persistence into

Brain-Behavior Measures in Psychosis Spectrum Youths of the Philadelphia
Neurodevelopmental Cohort
Council Meeting
10:30 am - 12:00 pm Panel Sessions

Session 1
Behavioral, Endocrine, and Neural Plasticity Changes Reflecting Stress Associated with Mouse
and Monkey Models of Heavy Alcohol Drinking
Chair: Howard Becker
Behavioral and Neural Adaptations Linked to Stress Associated with a Mouse Model of
Ethanol Dependence and Relapse Drinking
Behavioral and Endocrine Adaptations in a Monkey Model of Heavy Alcohol Drinking
o Kathleen Grant  Chronic Ethanol Exposure Increases Output from the Sensorimotor Striatum in Mouse
and Monkey Models via Changes in Neuronal Excitability and Synaptic Transmission
o David Lovinger  Similar Dopamine System Adaptations in Mouse and Monkey Models of Excessive
Alcohol Exposure

Session 2
Experimental Therapeutics and Drug Development Targeting Inflammation in Developmental
Chair: Eric Hollander
Gastrointestinal Symptoms in a Mouse Model of an Environmental Risk Factor for
Autism and Schizophrenia
o Paul Patterson  Immune System as a Target for Therapeutic Intervention in Neurodevelopmental
Disorders: Lessons from the Rett Syndrome
o Jonathan Kipnis  PET Imaging of Microglial Activation in Young Adults wit Autism Spectrum Disorder
o Kazuhiko Nakamura  Translational Experimental Therapeutics of Inflammation and Fever in Autism Spectrum
Disorder : Hot Tubs, Locus Coeruleus Modulation and Helminth Therapy
o Eric Hollander
Session 3
Applying Animal and Human Models of Risk Avoidance and Impulsivity to Understanding
Eating Disorders
Chair: Walter Kaye
A Translational Assessment of Reward-Based Learning in Adolescents with Bulimia
Harm avoidant behaviors and altered limbic and executive neural function in anorexia
Striatal Dopamine D2 Receptor Modulation of Risky Decision Making
D1- and D2-like Dopamine Receptors, Impulsive Temperament and Corticostriatal
Function as Related to Risky Decision-Making: Multimodal Imaging in Healthy Research

Session 4
Novel Molecules and Mechanisms in Vulnerability and Resilience Throughout Life
Chair: Marcelo Wood
miRNA programming in neurodevelopment: epigenetic targets in a dynamic landscape
Epigenetic Pathways During Early Postnatal Life: How does a Neuron “Know― to
Modulate its Epigenetic Machinery in response to Early-life Experience?
o Tallie Z. Baram  How neocortical Tet-mediated DNA hydroxymethylation regulates memory
o Timothy W. Bredy  Neuron-Specific Nucleosome Remodeling: A Missing Link in our Understanding of
Epigenetic Mechanisms underlying Intellectual Disability Disorders.
Session 5
Cognition, Biomarkers, and Longitudinal Outcomes in Geriatric Mood Disorders
Chair: Helen Lavretsky
Longitudnial BDNF Levels in Both an Elderly Cohort and an Inflammatory Cytokine-
Exposed Cohort: Risk for Cognitive Deficits
o Francis Lotrich  Late-life depression may increase risk of dementia but does not increase risk of
developing Mild Cognitive Impairment
Cognitive Control Network: Motivational Disturbances and Treatment Response of Late
Life Depression
o George Alexopoulos  Combination of methylpehnidate with citalopram is superior to either drug alone in
improving clinical and cognitive outcomes in geriatric depression.
o Helen Lavrtetsky
Session 6
The Insula Salience Network: Alterations in its Connectivity in Developmental, Anxiety, Mood
and Personality Disorders
Chair: Harold Koenigsberg
Insula - Conceptualizing Its Architecture, Function and Connectivity, with Applications
to Understanding Large-scale Brain Networks in Psychopathology and Autism
Insula-Amygdala Function and Connectivity in Trauma-Related Disorders: Relationship
to Childhood Maltreatment
Borderline Personality Disorder Patients Show Reduced Insula-Amygdala Functional
Connectivity and Fail to Habituate When Viewing Repeated Negative Emotional Pictures
o Harold Koenigsberg  Elevated Posterior Insula ventral Striatal Connectivity to Reward in Youth with Bipolar
Spectrum Disorders Relative to Youth with Other Behavioral and Emotional Dyregulation
Disorders: A Potential Neural Marker of Heightened Reward-related Perceptual Salience
in Bipolar Youth

Session 7
Strategies for the Development of Novel Therapies for Schizophrenia: From Clinic To
Laboratory (And Back Again)'
Chair: Joel Kleinman
Psychiatric GWAS Consortium triples schizophrenia GWAS sample-size to 31,000 cases
and 37,000 controls
Integrating the genome, epigenome, and transcriptome in the human brain: accounting
for biological and technical heterogeneity
Understanding ZNF804A: allelic variation, alternative transcripts, brain development and
Applying lessons from DISC1 to convert gene discoveries into drug discoveries
o Nicholas Brandon

Meeting Information


Everyone who attends the Annual Meeting must be
registered and must check in at the Meeting
Registration Desk to receive meeting materials.
People who are not registered or are registered as an
Accompanying Person will not be allowed into any
scientific sessions with the exception of the evening
poster receptions. Attendees must wear name badges
to be admitted into all sessions. The name badge policy will be strictly enforced. Meeting
registration can be completed online per the instructions below. Should you need a printed form,
please contact the Executive Office at 615-324-2360 or
Attendees may not videotape, audiotape, or photograph (camera or camera phone)
presentations at the ACNP Annual Meeting without prior permission from the panel chair.


ACNP Member Registrations:
To access the registration site, members must login to the ACNP website, www.acnp.org, select "Annual
Meeting" and click "Registration."
Invited Guest Registrations:
Guests will receive a link to the registration site in their invitation letter sent via email.
You are encouraged to pre-register for the Meeting before Thursday, October 31, 2013. All Meeting
registration fees will increase by $50.00 after this date.
In case of cancellation, please contact the ACNP Executive Office in writing no later than December 4, 2013,
to receive a refund less a $30.00 processing fee.

In December, average temperatures in Hollywood, Florida, range from a high of 74 degrees to a low of 65
degrees. The temperature of the meeting rooms may be somewhat warmer or cooler than you might expect.
You are encouraged to wear layered outer clothing.
Childcare options will be available at the Westin Diplomat Resort and Spa for ACNP attendees with children one year of age to 12 years of age. More information about childcare times and costs are available on the ACNP website.

Pre-Register for the Annual Meeting by October 31st


The Westin Diplomat is the conference hotel. The last day
for reservation acceptance at the discounted convention
rates is Wednesday, October 31st. You are urged to make
reservations as soon as possible, as availability is limited,
and rooms will likely sell out before the deadline.

: All rates are
single/double occupancy per night, and are exclusive of
applicable state and local taxes, which are currently 11%.
Rollaway beds (only allowed in king bedded rooms) and cribs can be requested and are complimentary. All
rooms have refrigerators. There is an additional $25 per night charge for each guest over two (2) adults sharing
the same room. Children up to 21 are free. Maximum of four adults are allowed in a room. In-Room Wireless
High Speed Internet Access USD 6.00 per day. Complimentary internet access is available in the hotel lobby.
The Westin Diplomat's guest rooms, common areas, and transportation services are in compliance with the
public accommodation requirements of the Americans with Disabilities Act. These facilities will be accessible to
and usable by individuals with disabilities who attend and participate in the Annual Meeting. If you have special
needs because of a physical disability, please contact the ACNP Executive Office at 615-324-2360.

All ACNP guests will be required to provide credit
card information during the online hotel reservation process to guarantee your reservation. This card will
only be charged if you fail to follow the CHANGE/CANCELLATION Policy below.

PRE/POST MEETING STAYS: ACNP discounted group rates are available three days before and three
days after meeting dates; space is limited and based on availability. If your preferred early arrival or late
departure dates are not available, you will be waitlisted and notified should they become available. Note: As
pre/post space is limited, we recommend that you make air travel plans after you receive your hotel

CHANGING YOUR RESERVATION: Please contact the Westin Diplomat In-House Reservations
at (954) 602-8700 Monday–Friday 8:00am-6:00pm Eastern.
CHANGES IN YOUR ARRIVAL DATE: Guests staying at the Westin Diplomat may make changes in
their arrival date without penalty up until 72 hours prior to scheduled arrival. Should you change your arrival
date to shorten your stay within 72 hours of your arrival date, your one night deposit will be forfeited.
CHANGES IN YOUR DEPARTURE DATE: Guests staying at the Westin Diplomat may change their
departure date up until the time of hotel check-in. You will be asked to re-confirm your date of departure
upon hotel check-in. Should you make a change in your departure date to shorten your stay after check in,
your one night deposit will be forfeited.
HOTEL CANCELLATION POLICY: Guests staying at the Westin Diplomat may cancel your room
without penalty up until 72 hours prior to scheduled arrival date. Should you cancel within 72 hours of your
arrival date, a one night deposit will be charged. Failure to arrive at the hotel on your scheduled arrival date
will result in the loss of your one night charge, and your room will be released for general sale.
SMOKE FREE: The Westin Diplomat Resort & Spa announces the introduction of the 'Breathe Westin'
program. In response to guest requests, every guest room and all indoor areas are now designated as 'smoke
free'. To assist guests who smoke in this transition, the Westin has additional seating and ash bins on the
resort grounds. Note: To ensure a refreshing experience upon each return, Westin Hotels & Resorts enforces
its smoke free policy in guest rooms and balconies with a $200 cleaning fee for violations.

Reservations are also available at the Crowne Plaza Hollywood Beach and the Hollywood Beach Marriott. Access to the ACNP room blocks is provided in your registration confirmation email. AIR TRAVEL AND GROUND
Air Travel: The closest airports to the ACNP headquarters hotel are the Hollywood/Fort Lauderdale
International Airport and the Miami International Airport. ACNP has secured discounted airfares with
American and Delta Airlines for travel to the ACNP 52nd Annual Meeting in Hollywood, Florida. The
ACNP has partnered with Caldwell Travel, Inc. for airline and car rental reservations. Please contact Lead
[email protected] at 615-277-9067, toll-free 800-229-3344, between the hours of 9:00a.m. and
5:30p.m. CST, Monday – Friday. (You may reach other fine travel consultants at Caldwell's Headquarters
Office between operational hours of 7:30a.m. and 5:30p.m. at 615-327-2720.)
Ground Transportation:
Rental Cars:
Hertz and Avis are offering special discounts to all ACNP attendees. To reserve your car rental call Caldwell
Travel at 615-277-9067 or 800-229-3344 or email
Ground Transportation:
By Taxi
Follow signs in either airport for ground transportation and taxi service. Fares range from $25 to $35 one
way to/from Fort Lauderdale/Hollywood International Airport and $60 to $80 one way to/from Miami
Shared Ride - Shuttle Service: Go Airport Shuttle and Executive Car Service provides airport/hotel
shuttle service from the Ft. Lauderdale Airport to the Westin Diplomat. One way fare is $13 (includes
gratuity). No reservations are needed for the transfer from the airport to the hotel; meet the shuttle at the
airport lower level curbside (maximum 30-minute wait for a shuttle, but most shuttles leave within ten
minutes). Shuttles stop at multiple hotels (up to 45 minutes) along the way. For return trip from the Westin
Diplomat to the Ft. Lauderdale airport, a reservation is required with minimum 24-hour notice. One way fare
is $13 (includes gratuity). Shuttle will make multiple stops on the return trip as well. To make a return
reservation, call 954-561-8888 or 800-244-8252, or

Private Transfer:
Go Airport Shuttle and Executive Car Service provides private airport/hotel transfers
from the Ft. Lauderdale Airport to the Westin Diplomat.
Arrival Transfer from Ft. Lauderdale Airport to Westin: No reservations are needed for this transfer
from the airport to the hotel; request a private sedan outside of baggage claim. Estimated 5-10 minute wait
for a sedan. One way fare is $45 (plus gratuity).

Arrival Transfer with Meet and Greet Service: You may arrange for a driver to meet you at baggage
claim with a sign bearing your name, assist you with your luggage, and transfer you to the Westin for a one
way charge of $63.25 (plus gratuity). Reserve by calling 954-561-8888 or 800-344-8252 or online at

Return Transfer from Westin Diplomat to Ft. Lauderdale Airport: For a return transfer from the Westin
to the Ft. Lauderdale airport via a private sedan, a reservation is required with minimum 24-hour notice. One
way fare is $45 (plus gratuity). To make a reservation, call 954-561-8888 or 800-244-8252, or
To make parking convenient valet and self-parking are available 24 hours a day. Self-parking is located at a
multi-level facility connected through a covered skywalk. Parking rates are: valet parking at $24 per day and
self-parking across the street at $20 per day with in/out privileges.
The 2013 ACNP Annual Meeting is jointly sponsored by the Vanderbilt University School of Medicine and the ACNP. This activity has been planned and implemented in accordance with the Essentials Areas and Policies of the Accreditation Council for CME (ACCME) through the joint sponsorship of Vanderbilt University School of Medicine and the ACNP. Vanderbilt University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Vanderbilt University School of Medicine designates this live activity for a maximum of 36.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. There will be a $40.00 charge for scientific registrants to obtain CME credits. CME instructions will be
available at the meeting registration desk and on the ACNP websit
It is the policy of Vanderbilt University School of Medicine and the ACNP to require disclosure of financial
relationships from individuals in a position to control the content of a CME activity; to identify and resolve
conflicts of interest related to those relationships; and to make disclosure information available to the
audience prior to the CME activity. Presenters are required to disclose discussions of unlabeled/unapproved
uses of drugs or devices during their presentations.
Program Overview/Statement of Need
The Annual Meeting of the American College of Neuropsychopharmacology is designed to meet the
educational needs of ACNP members and invited non-member colleagues. Current data suggests that in any
given year more than 20% of the U.S. adult population suffers from a diagnosable mental disorder. Four of
the ten leading causes of disability in the U.S. are psychiatric disorders, including schizophrenia, depression,
bipolar disorder, and obsessive-compulsive disorder. ACNP members have been among the leaders in
identifying underlying mechanisms for these disorders and developing new treatment strategies. The desired
results for the meeting are that ACNP members and their invited guests learn of the latest developments in
preclinical and clinical research being performed by their colleagues and world experts in order to 1)
enhance understanding of the neurobiological bases of current best practice approaches, 2) enhance
understanding of neurobiological and clinical science underpinnings in development of novel therapeutic
strategies, particularly for treatment-resistant forms of illness, and 3) lead to improvements in study designs
for proposed clinical and basic studies.
Target Audience
The target audience includes members of the American College of Neuropsychopharmacology and invited
experts. The audience includes physicians, psychologists, and basic neuroscientists from across the United
States as well as Europe and Asia. The physicians include a number of specialties, with psychiatrists
representing the majority of attendees, and neurologists next most common. Psychologists include clinical
psychologists and neuropsychologists.

Learning Objectives: After participating in this CME activity, participants should be able to:  Describe and discuss how the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area impact your current or potential future research projects.  Describe and discuss how you will change or modify a current approach or strategy in your current or potential future research projects based on what you learned from the results of recent or ongoing basic science and/or clinical studies of psychiatric disorders in your area of interest or a related area.  Describe and discuss how recent progress in identifying genetic variations that are risk factors for the development of psychiatric disorders affect your current or potential future research projects.
Americans with Disabilities Act
It is the policy of Vanderbilt University School of Medicine not to discriminate against any person
on the basis of disabilities. If you feel you need services or auxiliary aids mentioned in this act in
order to fully participate in this continuing education activity, please call the Executive Office at
615-324-2360 or send an email t
Register Online at

Source: http://d.plnk.co/ACNP/AM2013/ACNPAM2013PreliminaryProgram.pdf

No job name

Rizatriptan for the acute treatment of ICHD-II proposedmenstrual migraine: two prospective, randomized,placebo-controlled, double-blind studies LK Mannix1, E Loder2, R Nett3, L Mueller4, A Rodgers5, CM Hustad5, KE Ramsey5 & F Skobieranda51Headache Associates and ClinExcel Research, West Chester, OH, 2Headache Management Program, Spaulding Rehabilitation Hospital, Boston,MA, 3Texas Headache Associates, San Antonio, TX, 4University Headache Center, Stratford, NJ and 5Merck & Co., Inc., West Point, PA,USA

Les effets secondaires de la corticothérapie générale

PREVENTION DES COMPLICATIONS DE LA CORTICOTHERAPIE GENERALE DANS LES PEMPHIGUS DE L'ADULTE Catherine Prost Squarcioni Centre de Références Maladies Rares NET-DBAI-IDF Hôpital Saint Louis et hôpital Avicenne La cortisone, découverte en 1935, a transformé l'évolution de nombreuses maladies inflammatoires et auto-immunes (en particulier celle des pemphigus) qui étaient auparavant constamment mortelles. Depuis, la cortisone a été abandonnée au profit de nouvelles molécules encore plus efficaces et provoquant moins d'effets secondaires ; de nombreux progrès ont été faits pour prévenir ces derniers. Avant d'aborder précisément ce sujet, quelques remarques pour expliquer notre jargon médical et notre démarche thérapeutique dans les pemphigus. La corticothérapie générale s'utilisant de la même manière dans les différentes formes de pemphigus, en particulier dans les pemphigus vulgaires et les pemphigus superficiels, nous parlerons de pemphigus sans plus de précision. • On entend par corticothérapie générale (ou systémique) l'administration de corticoïdes par voie orale (par la bouche), intramusculaire ou intraveineuse (piqûres). En France, nous utilisons indifféremment :